How Bazemore was paid
$3.5M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.
Named executive officers
| Executive | Salary | Bonus | Stock | Options | Other | Total |
|---|---|---|---|---|---|---|
| Mark IwickiFormer Chief Executive Officer | $111,866 | — | $166,413 | $627,467 | $896 | $906,642 |
| Todd BazemoreFormer Interim Chief Executive Officer, President and Chief Operating Officer | $489,112 | $585,450 | $76,053 | $2,262,211 | $64,146 | $3,476,972 |
| Kim Brazzell, Ph.D.Former Head of Research and Development and Chief Medical Officer | $420,000 | $522,000 | $76,053 | $285,040 | $55,081 | $1,358,174 |
| Mary ReumuthFormer Chief Financial Officer | $438,962 | $475,550 | $76,053 | $285,040 | $47,002 | $1,322,608 |
What changed and why
- $3.5M$3,476,972 was Todd Bazemore’s 2025 total compensation, versus $949,550 in 2024.
- $281K$281,190 and $260,000 one-time retention bonuses were awarded to Bazemore and Brazzell, respectively.
- 50%50% and 45% were Bazemore’s and Brazzell’s 2025 target bonus percentages of base salary.
- $2.3M$2,262,211 of Bazemore’s 2025 compensation came from option awards.
- 96.7%96.7% of votes cast supported the 2025 advisory vote on executive compensation.
- All four named executive officers left the Company before some equity awards fully vested.
Other KALA BIO proxy statements
- 2025 proxy statement
Mark Iwicki paid $1.5M (-82% on the year).
Filed Dec 30, 2025
About this page
The figures were read out of the DEF 14A proxy statement on EDGAR by a language model and every number was then checked against the filing text; a figure that could not be found there is left out rather than shown. Totals follow SEC rules, which value stock and option awards at grant. Read the filing for footnotes and the compensation committee's full reasoning.